No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa < sup > ® < /sup > (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery

No significant difference in the risk of Acute Coronary Syndrome (including Myocardial Infarction) seen with Pradaxa < sup > ® < /sup > (dabigatran etexilate) compared to enoxaparin for VTE prevention after orthopaedic surgery
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news